Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells

Pathol Res Pract. 2023 Apr:244:154418. doi: 10.1016/j.prp.2023.154418. Epub 2023 Mar 18.

Abstract

Somatostatin is known to inhibit the secretion of various hormones by acting on endocrine cells through the somatostatin receptor 2 (SSTR2). Immunohistochemical evaluation of SSTR2 has become increasingly important in clinical practice to determine treatment strategies for patients with a neuroendocrine tumor (NET). Gastrointestinal (GI) tracts contain various neuroendocrine cells that constitute a diffuse endocrine system and some NETs are derived from those cells. In addition, NETs have been well known to express a variable spectrum of proteins shared by their normal cell counterparts of the specific anatomical sites. Thus, we may derive the kinetics of SSTR2 expression of NETs, including de novo expression, from the SSTR2 expression of the corresponding normal neuroendocrine cells. Therefore, a detailed study on the distribution of SSTR2 in normal human neuroendocrine cells may contribute to understanding the expression of SSTR2 in GI-NETs. However, the detailed cellular localization of SSTR2 in non-neoplastic neuroendocrine cells remains unknown. Therefore, we immunolocalized SSTR2 in neuroendocrine cells of normal human GI tracts, including the stomach, duodenum, ileum, and rectum, obtained from 41 surgically resected tissue specimens. Double immunohistochemistry of SSTR2 and hormones or hormone-associated proteins was performed. In all GI neuroendocrine cells, cell types other than D- and EC-cells demonstrated a high percentage of SSTR2-positive cases or a high double-positive ratio. In particular, EC-cells showed lower SSTR2-positive ratios in all sites. Midgut NETs, which often produce serotonin, are excellent targets for somatostatin analogs and are positive for SSTR2. Thus, we speculated that EC-cell NETs might lead to the de novo expression of SSTR2. In addition, a previous report showed high SSTR2 expression in ECL-cell NETs and gastrinomas, which could be because they are derived from neuroendocrine cells with high SSTR2 expression. This study may contribute to understanding the expression of SSTR2 in GI-NETs.

Keywords: Gastrointestinal tract; Immunohistochemistry; Neuroendocrine cell; Somatostatin receptor 2.

MeSH terms

  • Duodenum / pathology
  • Humans
  • Neuroendocrine Cells* / pathology
  • Neuroendocrine Tumors* / pathology
  • Receptors, Somatostatin* / metabolism
  • Somatostatin

Substances

  • Somatostatin
  • somatostatin receptor 2
  • Receptors, Somatostatin

Supplementary concepts

  • Gastro-enteropancreatic neuroendocrine tumor